Alder Biopharmaceuticals Inc (ALDR) Drops 6.05% on January 27

Equities Staff |

Alder Biopharmaceuticals Inc (ALDR) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 6.05% to $26.08, a loss of $-1.6799 per share. Starting at an opening price of $27.91 a share, the stock traded between $26.05 and $28.20 over the course of the trading day. Volume was 319,683 shares over 3,893 trades, against an average daily volume of 607,746 shares and a total float of 43.61 million.

The losses send Alder Biopharmaceuticals Inc down to a market cap of $1.14 billion. In the last year, Alder Biopharmaceuticals Inc has traded between $54.90 and $22.23, and its 50-day SMA is currently $33.46 and 200-day SMA is $37.26.

Alder BioPharmaceuticals Inc is a clinical-stage bio-pharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.

Alder Biopharmaceuticals Inc is based out of Bothell, WA and has some 87 employees. Its CEO is Randall C. Schatzman.

For a complete fundamental analysis analysis of Alder Biopharmaceuticals Inc, check out’s Stock Valuation Analysis report for ALDR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…